This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gruss, H. J. Articles by Carbone, A. Search for Related Content PubMed PubMed Citation Articles by Gruss, H. J. Articles by Carbone, A.

American Journal of Pathology, Vol 149, 469-481, Copyright © 1996 by American Society for Investigative Pathology

REGULAR ARTICLES

CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues

HJ Gruss, A Pinto, A Gloghini, E Wehnes, B Wright, N Boiani, D Aldinucci, V Gattei, V Zagonel, CA Smith, ME Kadin, C von Schilling, RG Goodwin, F Herrmann and A Carbone
Department of Medical Oncology and Applied Molecular Biology, Robert- Rossle Cancer Center, Humboldt University Berlin, Germany.

The CD30 ligand (CD30L) is a type II transmembrane glycoprotein of the tumor necrosis factor ligand superfamily. Recent cloning of CD30L has enabled studies to explore its function and tissue distribution. For instance, recombinant CD30L has been shown to co-stimulate T cells and to act as mitogen for Hodgkin's disease (HD)-derived cell lines. The counter-receptor for CD30L, ie, CD30, is a type I cytokine receptor that is highly expressed by activated T cells, Hodgkin and Reed- Sternberg (H-RS) cells, and anaplastic large cell lymphoma cells. In the present study, recombinant membrane-bound and soluble human CD30L were instrumental to raise a monoclonal antibody (M80) recognizing membrane-bound CD30L on transfected and native cells. With this reagent, a panel of cultured lymphoma-derived cell lines as well as primary normal, reactive, and HD-involved lymphoid tissues were examined for expression of CD30L by immunostaining and flow cytometry. In reactive lymphnodes and tonsils, CD30L was expressed by a small subset of lymphoid cells, histiocytes, and granulocytes. Higher levels of CD30L expression were noted in HD lesions among bystander cells; ie, T cells and granulocytes that surrounded H-RS cells. Native CD30L displayed at the cell surface was functionally active as shown by the ability of fixed granulocytes to interact with CD30+ cell lines. Moreover, CD30L was detectable, although to a lower staining intensity, in primary H-RS cells of all HD tissues investigated regardless of the histological subtype and the phenotype of H-RS cells (ie, CD30+/CD40+ versus CD30-/CD40+). Co-expression of CD30 and CD30L that was seen on H- RS cells of all, except the CD30- nodular lymphocyte predominant, subtypes of HD may point to the use of this pair of molecules in paracrine and/or autocrine mitogenic cell interactions. Monoclonal antibody M80 may thus represent a useful tool for studying CD30L expression on cultured cell lines and primary cells from normal, reactive, and malignant tissues.

This article has been cited by other articles:

				A. Chiu, W. Xu, B. He, S. R. Dillon, J. A. Gross, E. Sievers, X. Qiao, P. Santini, E. Hyjek, J.-w. Lee, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL Blood, January 15, 2007; 109(2): 729 - 739. [Abstract] [Full Text] [PDF]

				A. Younes and M. E. Kadin Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534. [Abstract] [Full Text] [PDF]

				B. F. Skinnider and T. W. Mak The role of cytokines in classical Hodgkin lymphoma Blood, May 29, 2002; 99(12): 4283 - 4297. [Abstract] [Full Text] [PDF]

				H. P. Hansen, S. Dietrich, T. Kisseleva, T. Mokros, R. Mentlein, H. H. Lange, G. Murphy, and H. Lemke CD30 Shedding from Karpas 299 Lymphoma Cells Is Mediated by TNF-{alpha}-Converting Enzyme J. Immunol., December 15, 2000; 165(12): 6703 - 6709. [Abstract] [Full Text] [PDF]

				M. E. Kadin Regulation of CD30 Antigen Expression and Its Potential Significance for Human Disease Am. J. Pathol., May 1, 2000; 156(5): 1479 - 1484. [Full Text] [PDF]

				R. von Wasielewski, S. Seth, J. Franklin, R. Fischer, K. Hubner, M. L. Hansmann, V. Diehl, and A. Georgii Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors Blood, February 15, 2000; 95(4): 1207 - 1213. [Abstract] [Full Text] [PDF]

				M. Mori, C. Manuelli, N. Pimpinelli, C. Mavilia, E. Maggi, M. Santucci, B. Bianchi, P. Cappugi, B. Giannotti, and M.E. Kadin CD30-CD30 Ligand Interaction in Primary Cutaneous CD30+ T-Cell Lymphomas: A Clue to the Pathophysiology of Clinical Regression Blood, November 1, 1999; 94(9): 3077 - 3083. [Abstract] [Full Text] [PDF]

				P. Romagnani, F. Annunziato, R. Manetti, C. Mavilia, L. Lasagni, C. Manuelli, G. B. Vannelli, V. Vanini, E. Maggi, C. Pupilli, et al. High CD30 Ligand Expression by Epithelial Cells and Hassal's Corpuscles in the Medulla of Human Thymus Blood, May 1, 1998; 91(9): 3323 - 3332. [Abstract] [Full Text] [PDF]

				V. Gattei, M. Degan, A. Gloghini, A. De Iuliis, S. Improta, F. M. Rossi, D. Aldinucci, V. Perin, D. Serraino, R. Babare, et al. CD30 Ligand Is Frequently Expressed in Human Hematopoietic Malignancies of Myeloid and Lymphoid Origin Blood, March 15, 1997; 89(6): 2048 - 2059. [Abstract] [Full Text] [PDF]